

## Resignation of a Board Member

Pisa, 16<sup>th</sup> April 2019 – Pharmanutra S.p.A. (“**Pharmanutra**” or the **Company**”) notifies that, – on the completion of a transaction to transfer Pharmanutra shares among some of its shareholders which took place today – the board member Gianni Lazzarini has submitted his irrevocable and unconditional resignation from the position as Director of Pharmanutra, with effect from today.

Gianni Lazzarini will continue to hold the office of President of the Board of Directors of the subsidiary Alesco S.r.l.

On the date of his resignation, Dr. Lazzarini, taking into account the completion of the aforementioned transfer transaction, holds 145,215 of the Company’s shares.

**Andrea Lacorte, President of Pharmanutra S.p.A, commented:** *“Gianni was fundamental in the launch and growth of Pharmanutra, actively contributing to the National success of our proprietary technologies. We are very happy to be able to count on Gianni Lazzarini’s valuable and continued collaboration for the marketing of the exclusive raw materials by our company Alesco Srl in the Italian nutraceutical and food industry”.*

Pharmanutra would like to offer its heartfelt thanks to Gianni Lazzarini for his contribution to the company, in appreciation of his work and the results delivered during his term of office.

### **PharmaNutra S.p.A.**

*Founded and guided by Chairman Andrea Lacorte and Vice Chairman Roberto Lacorte, PharmaNutra was established in 2003 and develops unique nutraceutical supplements and innovative nutritional devices, handling the entire production process, from the proprietary raw materials to the finished product. The effectiveness of its products has been demonstrated by numerous clinical studies, 91 of which have been published the involvement of over 6,000 patients. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 49 countries abroad, through 33 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL brand, where it boasts a number of important patents for sucrosomial technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

<http://www.PharmaNutra.it>

\*\* \*\*\* \*\*

*For Information:*

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b

56122 Pisa

Tel. +39 050 7846500

Fax +39 050 7846524

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Nomad & Specialist

**CFO SIM S.p.A.**

Via dell'Annunciata 23/4

20121 Milan

Tel. +39 02 303431

[ecm@cfosim.com](mailto:ecm@cfosim.com)

Press Office

**Spriano Communication&Partners**

Tel. +39 02 83635708

Matteo Russo - Cristina Tronconi

Mob. +39 347 9834881 +39 346 0477901

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

**Pharmanutra S.p.A.**

Sede Legale ed Operativa: Via delle Lenze, 216/b - 56122 Pisa (Italy)

tel. +39 050 7846500 | fax +39 050 7846524

Codice Fiscale, Partita IVA e N° di Iscr. Reg. Impr. Pisa: 01679440501

Capitale Sociale: € 1.123.097,70 i.v.

[www.pharmanutra.it](http://www.pharmanutra.it) | [info@pharmanutra.it](mailto:info@pharmanutra.it)